Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer
Daisuke Obinata
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Urology, Nihon University School of Medicine, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorKen-ichi Takayama
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorTomohiko Urano
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorTaro Murata
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorJinpei Kumagai
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorTetsuya Fujimura
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorKazuhiro Ikeda
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorKuniko Horie-Inoue
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorYukio Homma
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorYasuyoshi Ouchi
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorSatoru Takahashi
Department of Urology, Nihon University School of Medicine, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Satoshi Inoue
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Tel.: 81-3-5800-8834, Fax: 81-3-5800-9126
Department of Anti-Aging Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, JapanSearch for more papers by this authorDaisuke Obinata
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Urology, Nihon University School of Medicine, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorKen-ichi Takayama
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorTomohiko Urano
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorTaro Murata
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorJinpei Kumagai
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorTetsuya Fujimura
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorKazuhiro Ikeda
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorKuniko Horie-Inoue
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorYukio Homma
Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorYasuyoshi Ouchi
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorSatoru Takahashi
Department of Urology, Nihon University School of Medicine, Bunkyo-ku, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Satoshi Inoue
Department of Anti-Aging Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan
Division of Gene Regulation and Signal Transduction, Research Center for Genomic Medicine, Saitama Medical University, Bunkyo-ku, Tokyo, Japan
Tel.: 81-3-5800-8834, Fax: 81-3-5800-9126
Department of Anti-Aging Medicine, Graduate School of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-8655, JapanSearch for more papers by this authorAbstract
The androgen receptor (AR) plays a critical role in the development and the progression of prostate cancer. Alterations in the expression of AR coregulators lead to AR hypersensitivity, which is one of the mechanisms underlying the progression of prostate cancer into a castrate-resistant state. Octamer transcription factor 1 (Oct1) is a ubiquitous member of the POU-homeodomain family that functions as a coregulator of AR. In our study, the contribution of Oct1 to prostate cancer development was examined. Immunocytochemistry analysis showed that Oct1 is expressed in the nuclei of LNCaP cells. siRNA-mediated silencing of Oct1 expression inhibited LNCaP cell proliferation. Immunohistochemical analysis of Oct1 expression in tumor specimens obtained from 102 patients with prostate cancer showed a positive correlation of Oct1 immunoreactivity with a high Gleason score and AR immunoreactivity (p = 0.0042 and p < 0.0001, respectively). Moreover, patients with high immunoreactivity of Oct1 showed a low cancer-specific survival rate, and those patients with high immunoreactivities of both Oct1 and AR exhibited poorer cancer-specific prognosis. Multivariate hazard analysis revealed a significant correlation between high Oct1 immunoreactivity and poor cancer-specific survival (p = 0.012). These results demonstrate that Oct1 can be a prognostic factor in prostate cancer as a coregulator of AR and may lead to the development of a new therapeutic intervention for prostate cancer.
References
- 1 Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276–308.
- 2 Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835–9.
- 3 Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002; 23: 175–200.
- 4 Prefontaine GG, Lemieux ME, Giffin W, Schild-Poulter C, Pope L, LaCasse E, Walker P, Hache RJ. Recruitment of octamer transcription factors to DNA by glucocorticoid receptor. Mol Cell Biol 1998; 18: 3416–30.
- 5 Kutoh E, Stromstedt PE, Poellinger L. Functional interference between the ubiquitous and constitutive octamer transcription factor 1 (OTF-1) and the glucocorticoid receptor by direct protein-protein interaction involving the homeo subdomain of OTF-1. Mol Cell Biol 1992; 12: 4960–9.
- 6 Verrijzer CP, Van der Vliet PC. POU domain transcription factors. Biochim Biophys Acta 1993; 1173: 1–21.
- 7 Wang Q, Li W, Liu XS, Carroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380–92.
- 8 He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y, Xu K, Ni M, Lupien M, Mieczkowski P, Lieb JD, et al. Nucleosome dynamics define transcriptional enhancers. Nat Genet 2010; 42: 343–7.
- 9 Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28: 928–34.
- 10 Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, Ijichi N, Ouchi Y, Shirahige K, Aburatani H, Inoue S. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007; 26: 4453–63.
- 11 Kumagai J, Urano T, Ogushi T, Takahashi S, Horie-Inoue K, Fujimura T, Azuma K, Muramatsu M, Ouchi Y, Kitamura T, Inoue S. EBAG9 is a tumor-promoting and prognostic factor for bladder cancer. Int J Cancer 2009; 124: 799–805.
- 12 Saez AI, Artiga MJ, Sanchez-Beato M, Sanchez-Verde L, Garcia JF, Camacho FI, Franco R, Piris MA. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. Mod Pathol 2002; 15: 211–20.
- 13 Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200–6.
- 14 Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 1997; 57: 4511–6.
- 15 Jia L, Berman BP, Jariwala U, Yan X, Cogan JP, Walters A, Chen T, Buchanan G, Frenkel B, Coetzee GA. Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One 2008; 3: e3645.
- 16 Jariwala U, Cogan JP, Jia L, Frenkel B, Coetzee GA. Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions. Prostate 2009; 69: 392–400.
- 17 Ewen ME. Where the cell cycle and histones meet. Genes Dev 2000; 14: 2265–70.
- 18 Schild-Poulter C, Shih A, Yarymowich NC, Hache RJ. Down-regulation of histone H2B by DNA-dependent protein kinase in response to DNA damage through modulation of octamer transcription factor 1. Cancer Res 2003; 63: 7197–205.
- 19 Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001; 61: 4315–9.
- 20 Agoulnik IU, Vaid A, Bingman WE, 3rd, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65: 7959–67.
- 21 Marcelli M, Cunningham GR. Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999; 84: 3463–8.
- 22 Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002; 9: 155–70.
- 23 Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33–9.
- 24 Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34–45.
- 25 Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563–71.
- 26 Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437–46.
- 27 Wang L, Zou X, Berger AD, Twiss C, Peng Y, Li Y, Chiu J, Guo H, Satagopan J, Wilton A, Gerald W, Basch R, et al. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009; 1: 62–71.
- 28 Rosenblatt AE, Burnstein KL. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol 2009; 23: 412–21.
Citing Literature
